Peptide basics
One of these melanocortins is an approved medicine. The other has one trial
On this page
PT-141, generic name bremelanotide, has an FDA-approved product and 10 verified registered trials enrolling 2,644 people.
Melanotan II has one verified registered trial with 60 participants and no approved product anywhere.
Both act on melanocortin receptors, which is why they are grouped together and often confused.
The difference is not a matter of degree. One has been through regulatory review and the other has not.
This page compares the evidence and regulatory record of two related compounds. It is not advice, not a recommendation, and contains no dose, schedule or route. Melanotan II is not an approved medicine in any jurisdiction we are aware of.
The regulatory difference
PT-141 is bremelanotide, sold as VYLEESI. It has an FDA approval, which means a regulator reviewed a dossier covering manufacturing, labelling, safety and effectiveness for a specific use and agreed it could be marketed.1
Melanotan II has no approval in the FDA's records. Nothing about its manufacture, its purity, its labelling or its effects has been assessed by a regulator, and it is not a medicine in any sense the word normally carries.13
The evidence difference
- PT-141: 10 verified registered trials, 2,644 participants, furthest phase 4.
- Melanotan II: 1 verified registered trial, 60 participants, furthest phase 2.
- Melanotan I (afamelanotide): 23 verified trials, 999 participants, phase 3, FDA-approved as SCENESSE.23
A single 60-person phase 2 study is enough to say the compound has been given to people under a protocol. It is not enough to characterise what it does, and it is nowhere near enough to characterise harm.3
Why the confusion persists
They are structurally related melanocortin agonists, which means marketing can describe them in the same language without saying anything technically false. Words like melanocortin, receptor agonist and peptide apply equally to both.23
Readership shows the confusion is winning. Melanotan II draws 11,197 monthly views against PT-141's 9,091 — the unapproved compound is read about more than the approved one.234
Common questions
Are PT-141 and melanotan II the same compound?
No. They are distinct molecules in the same receptor family, with different structures, different regulatory status and very different evidence records.
Why does melanotan II have a trial at all if it is unapproved?
Compounds are studied for many reasons, and a registered trial does not imply a path to approval. Development stops for scientific and commercial reasons alike.
Does an FDA approval mean PT-141 is safe for everyone?
An approval covers a specific product for a specific population and use, with a label describing known risks. It is not a general statement about safety.
Sources
- RegulatoryDrugs@FDA — bremelanotide (VYLEESI) approval recordU.S. Food and Drug Administration, 2026www.accessdata.fda.gov/scripts/cder/daf/ ↗↩ Back to text
- RegulatoryClinicalTrials.gov search — intervention: bremelanotideU.S. National Library of Medicine, 2026clinicaltrials.gov/search?intr=bremelanotide ↗↩ Back to text
- RegulatoryClinicalTrials.gov search — intervention: melanotan IIU.S. National Library of Medicine, 2026clinicaltrials.gov/search?intr=melanotan+II ↗↩ Back to text
- Secondary sourceWikimedia REST API — English Wikipedia pageviewsWikimedia Foundation, 2026wikimedia.org/api/rest_v1/#/Pageviews%20data ↗↩ Back to text